Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a study for participants with advanced gastric or gastroesophageal junction
adenocarcinoma who have had tumor progression after first-line platinum-contained therapy.
The primary study hypotheses are that camrelizumab (SHR-1210) combined with apatinib prolongs
overall survival (OS) for participants with tumors that show positive programmed cell death
ligand 1 (PD-L1) expression.